Cannabidiol Nutraceuticals Market Size Worth $17.4 Billion By 2026

The global CBD nutraceuticals market is projected to reach USD 17.4 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to exhibit a CAGR of 18.8% during the forecast period. Introduction of the 2018 Farm Bill that legalized hemp cultivation and hemp-derived products in U.S., rising consumer preference for plant-based ingredients in dietary supplements, and awareness regarding the health benefits of cannabidiol are some of the factors powering the market growth. However, the easy availability of alternative products is obstructing market growth.

CBD tinctures dominated the global Cannabidiol (CBD) nutraceuticals market in 2018, with a revenue share of 42.6%. Increasing acceptance of cannabidiol for health and wellness purposes coupled with high bioavailability of tinctures when administered sublingually are the major factors responsible for this large market share. On the other hand, capsules and soft gels are anticipated to be the fastest-growing product type over the forecast period, as they are travel-friendly and convenient to carry in public places. However, many consumers dislike the raw taste and texture of cannabidiol and so they are switching towards capsules and softgels.

Based on the sales channel, retail store segment dominated the CBD (Cannabidiol) nutraceuticals market in 2018, as consumers prefer retail stores for buying dietary supplements due to attractive pricing. On the other hand, the online sales channel is expected to expand at the fastest CAGR over the forecast period owing to the rise in the preference for online shopping. Furthermore, the new entrants in the CBD nutraceuticals space, find online sales channel a much economical alternative than a retail storefront.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cbd-nutraceuticals-market

Further key findings from the report suggest:

In 2018, CBD tinctures dominated the Cannabidiol nutraceuticals market with a revenue share of 42.6%, due to the higher bioavailability than other product types
The online sales channel is projected to witness the fastest growth rate over the forecast period. Many companies are opting for this channel, as it is a faster way to reach the target audience
Some of the major market players are Medical Marijuana Inc.; CV Sciences Inc.; CHARLOTTE’S WEB; Irwin Naturals; and MGC Pharma

Heparin Market Size Worth $7.4 Billion By 2026

The global heparin market size is expected to reach USD 7.4 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 1.6% during the forecast period. Rising prevalence cardiovascular disorders, deep vein thrombosis, and renal diseases among other chronic diseases is expected to boost the growth.

According to the data published in the American Heart Association, in 2018, approximately 92.1 million American adults were living with some form of cardiovascular diseases. Coronary heart disease is one of the leading cause of deaths in U.S. Furthermore, it was estimated that more than 23.6 million deaths will be observed by 2030 due to cardiovascular diseases.

Increasing demand for transfusion of blood, blood components, and plasma derivatives during surgical procedures, treatment of infectious diseases, and increasing survival rate are high impact rendering drivers for growth of the heparin market during the forecast period. Increasing demand for RBCs and platelets by various hospital divisions and clinics is expected to have a positive impact on the growth.

Growing geriatric population is anticipated to propel the market growth. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, population aged 65 years and above is expected to reach 78 million whereas children under the age of 18 may reach around 76.7million.

Rising incidence of immunological diseases, thrombosis, and hemostasis is likely to result in high demand for therapeutic plasma proteins. Manufacturing of plasma proteins led to an increase in the demand for purified plasma, further expected to fuel the market over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/heparin-market

Further key findings from the report suggest:

Low molecular weight heparin led the type segment in 2018 owing to its more predictable anticoagulant effect
In 2018, ultra-low molecular weight heparin was estimated to be the fastest growing segment, owing to commercialization of enhanced version of products with improved pharmacological effects
Subcutaneous route of administration led the market in 2018 and is estimated to be the fastest growing segment over the forecast period due to ease of administration
Coronary artery disease was considered to be the largest application segment in 2018 and venous thromboembolism is projected to be the fastest growing segment in near future
In 2018, outpatient led the end use segment and was estimated to register the fastest growth in the forthcoming years
North America held the largest market share in 2018 owing to increasing prevalence of cardiovascular disorders and sports injuries. Asia Pacific is estimated to be the fastest growing segment over the forecast period
Some of the key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd

Psoriatic Arthritis Treatment Market Size Worth $18.6 Billion By 2026

The global psoriatic arthritis treatment market size is expected to reach over USD 18.6 billion by 2026, according to a new study by Grand View Research Inc. It is projected to expand at a CAGR of 10.1% during the forecast period. Emergence of biosimilars, new product launches, and a rising consumer awareness are some of the key factors driving the growth.

Biologics generated the highest revenue among other drug classes, in 2018. The segment growth is driven by the demand for targeted therapy, improved safety & efficacy profiles, anticipated launches of several promising pipeline candidates, and strong commercial performances of existing products. DMARDs is also expected to maintain a steady growth rate, supported by the first-line action of corticosteroids as well as the impending launch of JAK-inhibitors and TYK2 kinase inhibitors.

North America captured the highest market share in 2018, propelled by high healthcare expenditure, disease prevalence, regional presence of key manufacturers, and rapid rise in consumer awareness. Asia Pacific is expected to demonstrate the fastest regional growth over the forecast period, driven by a rising trend of biosimilars, improvement in healthcare infrastructure, and increasing disposable income.

Some key players in the psoriatic arthritis (PsA) treatment market include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer, Inc.; and UCB S.A.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/psoriatic-arthritis-psa-treatment-market

Further key findings from the study suggest:

Biologics captured over 50% share of the psoriatic arthritis treatment market in 2018. The segment is anticipated to witness growth, attributed to the launch of infliximab, guselkumab, bimekizumab, risankizumab, and tildrakizumab
Upadacitinib, filgotinib, and BMS-986165 —upon launch — are likely to have a positive impact on the growth rate of DMARDs
Injectables accounted for the largest PsA treatment market share among other routes of administration in 2018
North America and Europe, collectively, captured more than half the revenue share in 2018 and are anticipated to witness significant growth in the forthcoming years

Polycystic Ovarian Syndrome Treatment Market Worth $5.1 Billion By 2025

The global polycystic ovarian syndrome treatment market is expected to reach USD 5.1 billion by 2025, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/polycystic-ovarian-syndrome-pcos-treatment-market

Further Key Findings from the Study Suggest:

Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS
Key players in the market include AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc., Bristol-Myer Squibb Company, and Novartis AG. The market also includes other emerging players such as Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals, Inc., which are expected to grow significantly in the near future.

Laboratory Proficiency Testing Market Size Worth $1.9 Billion By 2027

The global laboratory proficiency testing market size is expected to reach USD 1.9 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2020 to 2027. The market is driven by the increasing focus on water tests, legalization of medical cannabis, a growing number of cannabis testing laboratories, and increasing outbreaks of foodborne illnesses.

Government initiatives to carry out accurate and reliable proficiency testing are expected to drive the market. For instance, in October 2020, the Central Testing Laboratory of the Abu Dhabi Quality & Conformity Council implemented a PT program in collaboration with Biogenix Lab to verify the competency of medical laboratories carrying out COVID-19 tests.

Initiatives undertaken by the governments to raise awareness are anticipated to further boost market growth. For instance, in November 2020, the National Accreditation Board for Testing and Calibration Laboratories’ (NABL-IGS) awareness program was conducted to raise awareness about the significance of accrediting geotechnical laboratories in Kerala, India.

The increasing adoption of fully-automated instruments and automation in laboratories is expected to boost market growth. The presence of accreditation programs aimed to combat challenges, such as safety and complexity in the food supply chain, is expected to boost market growth. For instance, in March 2020, AOAC INTERNATIONAL expanded its Laboratory PT Program by adding testing for infant formula and adult nutritional and pH to ensure safety in the food supply chain.

The presence of new environmental protection regulations due to COVID-19 is expected to boost market growth. For instance, in June 2020, the Environmental Diagnostics Laboratory (EDLab) at Pure Air Control Services was accredited by the A2LA for testing environmental SARS-CoV-2

The market is highly competitive as there are a large number of organizations providing various programs. Furthermore, the prices vary between the organizations based on programs and additional discounts. The companies are focusing on the use of automated instruments and new programs continue gaining profits in the market. These new programs, coupled with the growing demand for safety and efficacy of food products and diagnostics owing to the SARS-CoV-2 pandemic, are expected to intensify competition over the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/laboratory-proficiency-testing-market

Further key findings from the report suggest:

The legalization of cannabis products in the U.S. in December 2018 and the gradual expansion of this market are propelling the need for the testing of safety and efficacy for medical use
The presence of food contaminants can cause more than 200 diseases, including diarrhea and cancer. Diarrhea affects nearly 550 million people and causes 230,000 deaths every year. Children aged below 5 years carry 40% of foodborne diseases, causing 125,000 deaths every year
In the U.K., over 130 million hematology tests are carried out each year
Calibration proficiency testing is another service being focused on, which is attributed to the growing scope of automation in laboratories
Organizations such as the American Proficiency Institute, LGC Ltd., and the College of American Pathologists developed several programs for laboratories to improve their quality and assess performance in testing COVID-19

Spinal Muscular Atrophy Treatment Market Size Worth $3.9 Billion By 2025

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute to the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market

Further key findings from the study suggest:

The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
Based on disease type, type 1 accounted for the largest revenue share owing to the rising incidence of type 1 SMA
By treatment, the drug segment accounted for the largest revenue share in 2017
North America will retain its lead as the largest regional market; however, Asia Pacific is anticipated to register the fastest CAGR over the forecast period
The market is presently led by Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post-2020

Rigid Packaging Market Worth $848.71 Billion By 2025

The global rigid packaging market size is projected to reach USD 848.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.7% during the forecast period. Increasing demand for sustainable packaging is expected to augment the market over the forecast period.

Packaging is a process of protecting and enclosing goods for storage, distribution, and sale. Rigid packaging is a type of packing which is characterized by high stiffness, impact strength, and barrier properties. It is offered in several forms, including jars, containers, bottles, and cans.

Raw materials required for manufacturing of rigid packing include metals, paper & paperboard, glass, and plastic. Suppliers of these materials are present worldwide, making the market fragmented. Rio Tinto and Alcoa are some of the key suppliers of metals such as aluminum, while ArcelorMittal is the largest steel manufacturer in the world.

Final products are sold by distributors, retailers, and wholesalers. Major players in this stage include Packaging Supplies Ltd., Packing Suppliers of America, Paper Mart, and Packaging Centre. Some of the manufacturers have adopted integration wherein they sell the products through exclusive outlets.

Rigid packaging accounted for over 80.0% of the total packing industry in 2016. However, flexible packing offers more advantages as compared to rigid ones such as lightweight, energy savings, small pack size, ease of transportation & storage, and convenient disposal. Hence, the flexible packing market is expected to make inroads in the rigid packaging market in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/rigid-packaging-market

Further Key Findings from the Report Suggest:

In terms of materials, plastics dominated the market in 2015 and it is anticipated to witness a CAGR of 6.4% in terms of volume over the forecast period
Paper & paperboard is expected to register a CAGR of 7.1% in terms of revenue during the same period. Recyclability of the material has made it the most commonly used product in the industry
The personal care application segment is anticipated to rise at a CAGR of 6.3% in terms of revenue over the coming year due to increasing demand for personal care products
Asia Pacific is estimated to post a CAGR of 7.6% in terms of revenue from 2016 to 2025 due to increasing demand from China and India
In August 2016, Berry Plastics Group, Inc. acquired AEO Industries Inc. in the U.S. This acquisition strengthened the company’s position in the North America market.

Pregnancy Care Products Market Size Worth $33.22 Million By 2025

The global pregnancy care products market size is expected to reach USD 33.22 million by 2025 at a 5.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing awareness regarding use of personal care products during pregnancy and high adoption of organic products are driving the market.

A shift in trend toward adoption of organic maternity personal care products owing to safety concerns over chemical-based products is changing the scenario of the overall market. Furthermore, new as well as existing players are introducing organic or herbal variants to increase their market presence and product positioning. In addition, rising awareness and increasing influence of advertising and social media campaigns are boosting the adoption of pregnancy care products.

Doctors do not recommend the use of certain chemicals such as salicylic acid, retinol, toluene, and beta hydroxy acids during pregnancy as they pose a threat to both mother and baby. This has impeded the growth of chemical-based pregnancy care products.

Stretchmark minimizers is the largest segment of the global pregnancy care products market owing to rising concern of stretchmarks during gestation period. Breast creams and toning/firming lotions are expected to experience lucrative demand over the forecast period owing to increasing awareness and rising focus regrading post pregnancy body. Asia Pacific emerged as the dominant regional market owing to highest number of pregnancies and rising cognizance regarding adoption of pregnancy care products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pregnancy-care-products-market

Further key findings from the report suggest:

Stretchmark minimizers emerged as the largest segment owing to their high demand during pregnancy and rising awareness regarding the product
Asia Pacific dominated the market in 2017. Higher number of births and rising awareness among expecting mothers have facilitated the dominance of this region
Latin America is projected to witness rapid growth during the forecast period owing to rapid adoption of organic variants of pregnancy care products and increased product availability owing to telemarketing and other social media platforms
Some of the key players are Mama Mio US Inc.; Noodle & Boo Novena Maternity; Expanscience Laboratories, Inc.; E.T. Browne Drug Co., Inc.; and Clarins Group.

Migraine Drugs Market Size Worth $7.8 Billion By 2025

The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

Further key findings from the report suggest:

Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
Biohaven’s rimegepant is expected to face competition from Allergan’s ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (a combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Women’s Health Market Size Worth $47.8 Billion By 2027

The global women’s health market size is expected to reach USD 47.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 4.9% over the forecast period. Governments and various private organizations focused on women health across the globe, which is likely to drive the market in the coming years. Coverage plans provided to women is one of the key factors expected to drive the market in developed countries.

In U.S., coverage plans provide preventive services for women without any copayment charges. This includes anemia screening on a routine basis, folic acid supplements for women who may become pregnant, hepatitis B screening, breast cancer screening, and contraception. Healthy People 2020 was established by the Department of Health and Human Services which has a 10-year agenda for improving the health of all Americans.

Initiatives undertaken by countries such as India, Japan, China, Singapore, and Australia are expected to drive the market over the forecast period. For example, in September 2016, Australia’s Ministry of Health provided a grant of USD 3.8 million till 2019 to Jean Hailes, a women’s health group, to help develop its education and outreach.

Owing to aging and rising incidences of obesity, an increase in prevalence of osteoarthritis (OA) has been witnessed. According to the United Nations, about 10%-15% of all adults aged over 60 have some degree of OA, and the condition is more prevalent in women. According to the CDC, in 2013, back problems were more common in women (30.2%). According to the International Osteoporosis Foundation (IOF), the worldwide prevalence of osteoporosis among women was over 200.0 million in 1990, which is anticipated to reach 680.0 million by 2050.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/womens-health-market

Further key findings from the study suggest:

On the basis of application, the women’s health market is segmented into postmenopausal osteoporosis, endometriosis, hormonal infertility, contraceptives, and polycystic ovary syndrome (PCOS) and menopause. Contraceptives held a majority of the market share in terms of revenue in 2019
Availability of a wide range of drugs for the treatment of postmenopausal osteoporosis is projected to boost the market. These include Fosamax, Actonel, Boniva, Reclast, Evista, and Prolia. In April 2017, the U.S. FDA approved a new drug, Tymlos, to treat postmenopausal osteoporosis. The approval was based on data of an 18-month trial that demonstrated a substantial reduction in the risk of vertebral and non-vertebral fractures
North America held the largest market share in 2019 owing to technological advancements and presence of major market players in the region. Asia Pacific, on the other hand, is expected to witness the highest growth rate over the forecast period
Some of the key players in the women’s health market are Bayer AG; Allergan; Merck & Co., Inc.; Teva Pharmaceuticals; Pfizer; Agile Therapeutics; Amgen, Inc.; AstraZeneca, Bristol-Myers Squibb, and Ferring B.V.